Objective:

To evaluate the efficacy of teclistamab, a BCMA-targeted bispecific antibody, in patients with high-risk smoldering multiple myeloma compared to standard therapy.

Approach:

• Trial Design: Phase 2 ImmunoPRISM trial, randomized study involving 59 patients with high-risk smoldering multiple myeloma.
• Treatment Groups: 45 patients received teclistamab; 14 patients received lenalidomide plus dexamethasone.

Key Findings:

• 75.6% of teclistamab patients achieved a complete response compared to none in the combination therapy group.
• 82% of teclistamab patients became MRD-negative, while none in the combination therapy group achieved MRD negativity.
• Teclistamab significantly improved progression-free survival, with only 7% of patients progressing after a median follow-up of 23.4 months compared to 36% in the combination group.
• Estimated 92% of teclistamab patients will be alive and disease-free after two years versus 51% with the combination therapy.

Interpretation:

Teclistamab demonstrates superior efficacy in achieving deeper responses and prolonging progression-free survival in high-risk smoldering multiple myeloma compared to lenalidomide plus dexamethasone.

Limitations:

• Small sample size with only 59 patients enrolled.
• Short median follow-up duration of 23.4 months.

Conclusion:

Teclistamab may represent a promising early intervention strategy for high-risk smoldering multiple myeloma, potentially altering disease progression.

Sources:

• Dana-Farber Cancer Institute